Physician profile
Josiane Lederman
NPI 1619981511
$20,185.24
in general payments reported to CMS, 2019-2025
30 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,987 · 2020: $1,874 · 2021: $3,198 · 2022: $2,706 · 2023: $4,765 · 2024: $1,632 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,053 · Education: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,053.43 |
| Education | $365.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $13,350.21 | 2019-2025 | Xeomin |
| Janssen Biotech, INC. | $3,170.57 | 2019-2025 | Tremfya, Stelara, Simponi |
| Galderma Laboratories, L.P. | $452.20 | 2019-2025 | Nemluvio, Twyneo, Aklief |
| Medimetriks Pharmaceuticals, INC. | $350.00 | 2020 | |
| Lilly USA, LLC | $301.85 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $301.46 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $261.15 | 2019-2025 | |
| Leo Pharma INC. | $220.79 | 2019-2025 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.42 | 2022-2024 | Cyltezo |
| Abbvie INC. | $186.30 | 2020-2025 | |
| Pfizer INC. | $139.27 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $138.29 | 2020-2025 | |
| Dermavant Sciences, INC. | $124.04 | 2023-2024 | Vtama |
| Almirall LLC | $120.68 | 2021-2025 | Seysara |
| Janssen Scientific Affairs, LLC | $112.25 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $111.33 | 2020-2025 | Otezla |
| Botanix Sb INC | $101.37 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $100.29 | 2023-2025 | Zoryve |
| Ucb, INC. | $77.99 | 2021-2025 | Bimzelx |
| Incyte Corporation | $65.99 | 2021-2025 | Opzelura |
| Revance Therapeutics, INC. | $53.99 | 2024-2025 | Daxxify |
| Biofrontera INC. | $51.46 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $43.69 | 2025 | Libtayo, Dupixent |
| Dermira, INC. | $34.04 | 2020-2021 | |
| Organon LLC | $33.08 | 2025 | Vtama |
| Sanofi-Aventis U.S. LLC | $23.55 | 2019 | |
| Paratek Pharmaceuticals, INC. | $18.66 | 2024 | Nuzyra |
| Allergan, INC. | $15.36 | 2020 | |
| Sandoz INC. | $14.07 | 2019 | |
| Journey Medical Corporation | $13.89 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josiane Lederman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.